Short-Wave Excitations in Non-Local Gross-Pitaevskii Model

It is shown, that a non-local form of the Gross-Pitaevskii equation allows to describe not only the long-wave excitations, but also the short-wave ones in the systems with Bose-condensate. At given parameter values, the excitation spectrum mimics the Landau spectrum of quasi-particle excitations in superfluid Helium with roton minimum. The excitation wavelength, at which the roton minimum exists, is close to the inter-particle interaction range. It is shown, that the existence domain of the spectrum with a roton minimum is reduced, if one accounts for an inter-particle attraction.Comment: 5 pages, 5 figures, UJP style; presented at Bogolyubov Kyiv Conference "Modern Problems of Theoretical and Mathematical Physics", September 15-18, 200

Short-Living Defects and Recombination Processes in Li 6Gd(BO3)3 Crystals

Results of a study of transient optical absorption (TOA) and luminescence of lithium-gadolinium orthoborate Li6Gd(BO3)3 (LGBO) in the visible and ultraviolet spectral regions are presented. As revealed by absorption optical spectroscopy with nanosecond time resolution, the LGBO TOA derives from optical transitions in hole centers, with the optical density relaxation kinetics being mediated by interdefect tunneling recombination involving these centers and neutral lithium atoms acting as electronic Li0 centers. At 290 K, the Li0 centers are involved in thermally stimulated migration, which is not accompanied by carrier transfer to the conduction or valence band. The slow TOA decay kinetics components, with characteristic times ranging from a few milliseconds to seconds, have been assigned to diffusion-limited annihilation of lithium interstitials with vacancies. The mechanisms responsible for the creation and relaxation of short-living Frenkel defect pairs in the LGBO cation sublattice have been analyzed. © 2009 Elsevier Ltd. All rights reserved

Механизмы развития антипсихотик-индуцированных метаболических нарушений: фармакогенетический аспект

Antipsychotics are the main drug group in the treatment of disorders of the schizophrenic spectrum. At the same time, this drug group requires long-term use, has a narrow therapeutic breadth and a large spectrum and high severity of undesirable drug reactions, the manifestation of which is largely determined by the patient’s genotype. In this connection, the severity of undesirable drug reactions in drugs of the first and second generation of antipsychotics is different. Atypical antipsychotics, unlike typical antipsychotics, have a significantly lower chance of causing extrapyramidal disorders, though they primarily induce metabolic side effects, consisting of significant weight changes, glucose metabolism dysregulation, and dyslipidemia. These unwanted drug reactions significantly reduce adherence to therapy and can lead to serious complications in the future. At the same time, experience with the use of atypical antipsychotics has shown that the severity of unwanted reactions differs within the group of atypical antipsychotics and, more importantly, even for one drug taken by different patients, is a variable index. The reason for this phenomenon lies is in the polymorphism of the pharmacokinetic and pharmacodynamic factors involved in the metabolism of atypical antipsychotics and the different chemical structure of the drugs. The study of the effect of various combinations of polymorphic variants of the pharmacokinetic and pharmacodynamics factors on the development of antipsychotic-induced metabolic disorders is a complex and high-priority task of personalized medicine. Антипсихотики являются основными лекарственными препаратами в терапии расстройств шизофренического спектра. Антипсихотические препараты требуют длительного применения, обладают узкой терапевтической широтой, большим спектром и выраженностью нежелательных лекарственных реакций, проявление которых во многом определяется генотипом пациента. Выраженность нежелательных лекарственных реакций у препаратов первой и второй генераций антипсихотиков различна.Применение атипичных антипсихотиков, в отличие от типичных, реже вызывает экстрапирамидные расстройства, но индуцирует, прежде всего, метаболические нарушения: изменение веса, дизрегуляцию метаболизма глюкозы, дислипидемию. Перечисленные нежелательные лекарственные реакции в значительной мере снижают приверженность пациентов к терапии и могут привести к серьезным осложнениям в дальнейшем. Клинический опыт применения антипсихотиков показал, что выраженность нежелательных реакций одного препарата, принимаемого различными пациентами, является вариабельным показателем в связи с полиморфизмом генов фармакокинетических и фармакодинамических факторов, задействованных в реализации фармакологического действия антипсихотиков. В связи с этим изучение влияния различных комбинаций полиморфных вариантов генов фармакокинетических и фармакодинамических факторов на развитие антипсихотик-индуцированных метаболических нарушений является приоритетной задачей персонализированной психиатрии.

Measurement of the e+e−→π+π−e^+e^-\to\pi^+\pi^- cross section from threshold to 1.2 GeV with the CMD-3 detector

The cross section of the process $e^+e^-\to\pi^+\pi^-$ has been measured in the center of mass energy range from 0.32 to 1.2 GeV with the CMD-3 detector at the electron-positron collider VEPP-2000. The measurement is based on a full dataset collected below 1 GeV during three data taking seasons, corresponding to an integrated luminosity of about 62 pb$^{-1}$. In the dominant $\rho$-resonance region, a systematic uncertainty of 0.7% has been reached. At energies around $\phi$-resonance the $\pi^+\pi^-$ production cross section was measured for the first time with high energy resolution. The forward-backward charge asymmetry in the $\pi^+\pi^-$ production has also been measured. It shows the strong deviation from the theoretical prediction based on conventional sQED framework and is in good agreement with GVDM and dispersive-based predictions. The impact of presented results on the evaluation of the hadronic contribution to the anomalous magnetic moment of muon is discussed.Comment: 52 pages, 36 figures; cosmetic changes of the text, fix fig.2 , fix comment on used selection cuts in the attached radiative correction tabl

Measurement of the pion formfactor with CMD-3 detector and its implication to the hadronic contribution to muon (g-2)

The cross section of the process $e^+e^-\to\pi^+\pi^-$ has been measured in the center of mass energy range from 0.32 to 1.2 GeV with the CMD-3 detector at the electron-positron collider VEPP-2000. The measurement is based on an integrated luminosity of about 88 pb$^{-1}$ out of which 62 pb$^{-1}$ constitutes a full dataset collected by CMD-3 at center-of-mass energies below 1 GeV. In the dominant region near $\rho$-resonance a systematic uncertainty of 0.7% has been reached. The impact of presented results on the evaluation of the hadronic contribution to the anomalous magnetic moment of muon is discussed.Comment: 6 pages, 3 figure